Signadori Bio, a preclinical-stage biopharmaceutical company developing a next generation, off-the shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumours, recently announced the appointment of Dr. Selwyn Ho as Chief Executive Officer.
Dr. Ho is an experienced biopharma and biotech executive, with nearly 30 years of experience across commercialisation, drug development and multiple pre-& post-product launches, with a focus in ophthalmology, immunology and immuno-oncology, leveraging cell therapy, monoclonal antibodies and multi-specific antibody modalities.
Most recently, Dr. Ho was Chief Executive Officer of Medigene AG, a German publicly listed, immuno-oncology company, developing T cell receptor (TCR) guided modalities for the treatment of solid tumours, including autologous TCR-T cell therapies, off-the shelf TCR-T cell engagers (TCR-TCE) and other allogeneic TCR guided cell modalities. At Medigene, Dr. Ho led the strategic pivot into the development off-the shelf treatments, whilst advancing the lead autologous cell therapy programme into a successful IND and CTA approval. Prior to this, Dr. Ho was EVP, Chief Business Officer at Connect Biopharma, a US, immunology focused biotech listed on NASDAQ (CNTB), where he supported the successful crossover financing, subsequent upsized, over-subscribed IPO, and the build out of the company’s US operations and footprint.
“Signadori Bio’s vision to develop a next generation, in vivo engineered monocyte therapy for solid tumours, based on P21 expression, aims to address many of the challenges and unmet needs currently seen with immunotherapies and autologous cell therapies,” said, Dr. Selwyn Ho, Chief Executive Officer, Signadori Bio.
“I am excited for the significant potential of our unique approach, supported by promising early pre-clinical data. I look forward to working closely with Matthieu Coutet, Sofinnova Partners, our investors, and our co-founders Dr. Jean-Luc Perfettini and Prof. Nathalie Chaput-Gras as well as building on the excellent research from Gustave-Roussy, together with our team of dedicated scientists, to advance the company toward its next set of milestones,” he added.
“Selwyn brings a rare combination of strategic leadership and deep operational experience in immuno-oncology and advanced therapies, which makes him uniquely suited to lead Signadori Bio at this stage. We have strong conviction in the company’s differentiated monocyte platform and the quality of the team and look forward to supporting its continued progress toward the clinic,” said Matthieu Coutet, Partner, Sofinnova Partners.
“Selwyn’s appointment marks an important milestone for Signadori Bio, and we warmly welcome him to the team. As co-founders, we remain deeply committed to the scientific vision that underpins our platform, harnessing the immune potential of gene-modified monocytes to address unmet needs in solid tumour treatment. We are confident that Selwyn’s expertise will accelerate our path to the clinic”, said Dr Jean-Luc Perfettini and Professor Nathalie Chaput, Co-founders, Signadori Bio.
